Loading market dashboard
Globus Medical, Inc.
GMEDHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
NEW YORK, June 1, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders. The investigation seeks to determine whether Globus Medical's directors breached their fiduciary duties in connection with recent corporate actions.
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
On May 20, 2026, Globus Medical Inc (GMED) shares rose 5.1% today, reaching a current price of $84.03. The stock is trading within a 52-week range of $51.79 to
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
The heavy selling pressure might have exhausted for Globus Medical (GMED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Globus Medical NYSE: GMED reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and contributions from its Nevro acquisition.
Globus Medical beats Q1 EPS estimates by 22% as revenues rise 27% to $759.9M; margins widen and 2026 EPS outlook up, lifting shares 5.8%.
Globus Medical (GMED) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.68 per share a year ago.
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
WKC, VAC, CLAR, CNK and GMED have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2026.
ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet tops Q1 EPS and revenue estimates with strong segment growth and margin expansion, yet shares slip 1.8% premarket after results.
Globus Medical, Inc. (NYSE: GMED - Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,831,226 shares, a decline of 14.0% from the March 15th total of 3,293,919 shares. Based on an average daily volume of 991,496 shares, the days-to-cover ratio
AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the market close on Thursday, May 7, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Robotics stocks like GMED, ADSK, MCHP and ROK gain momentum as physical AI, automation and medical robotics drive a major industry growth wave in 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GMED rides on NuVasive synergies, strong cash flow and rapid innovation, but macro pressures and rising costs cloud its near-term outlook.
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BE, SM, KRUS, GMED and BP have been added to the Zacks Rank #1 (Strong Buy) List on April 8th, 2026.
Flowserve, California Resources and Globus Medical stand out as sales-growth buys as oil spikes and Iran-Strait tensions shake markets.
Allspring Global Investments Holdings LLC trimmed its stake in shares of Globus Medical, Inc. (NYSE: GMED) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 447,174 shares of the medical device company's stock after selling 29,357
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026.
GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.
Bridgefront Capital LLC acquired a new stake in Globus Medical, Inc. (NYSE: GMED) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 11,642 shares of the medical device company's stock, valued at approximately $667,000. Several other institutional investors and hedge funds also
ArrowMark Colorado Holdings LLC increased its holdings in Globus Medical, Inc. (NYSE: GMED) by 25.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,202,488 shares of the medical device company's stock after purchasing an additional 241,236 shares
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
Globus Medical (GMED) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
